Dr Vadivel Parthsarathy

Position: Lecturer in Biomedical science

College: College of Life & Natural Sciences

Department: Biosciences

Subject area: Biological Sciences

Show All


Lecturer in Biomedical sciences

Teaching responsibilities

Foundation: Research methods in Human Biology

Chemistry of life, Concepts of Human Health and Wellbeing, Genetics

Biomedical Professional practice, The Cell, Human Physiology and Disease

Cell Signalling in Health and Disease, Bio innovation

Research interests

1) Diabetes and neuro-cognition

2) Neurodegenerative disorders

3) Drug development

Membership of professional bodies

Member of the IBMS 

Member (Diabetes UK),

Member of Irish Endocrine Society


Post Graduate Certificate in Higher education Practice (2016)

PhD. in Biomedical Sciences (2013)

MSc Biotechnology (2009)

BSc Medical Laboratory Technology (2001)

Recent publications

  • O’Harte FPM, Parthsarathy V, Hogg C, Flatt PR (2017) Acylated apelin-13 amide analogues exhibit enzyme resistance and prolonged insulin releasing, glucose lowering and anorexic properties. Biochemical Pharmacology (Accepted). BCP-D-17-00764R1
  • Parthsarathy V, Hogg C, O’Harte FPM, Flatt PR (2017) Beneficial long-term antidiabetic actions of N- and C-terminally modified analogues of apelin-13 in diet-induced obese diabetic mice. Diabetes Obesity Metabolism (Accepted) doi: 10.1111/dom.13068. 
  • Millar P, Pathak N, Parthsarathy V, Bjourson AJ, O'Kane M, Pathak V, Moffett RC, Flatt PR, Gault VA. (2017) Metabolic and neuroprotective effects of dapagliflozin and liraglutide in diabetic mice. Journal of Endocrinology. Doi:10.1530/JOE-17-0263. 
  • Hasib A, Ng MT, Gault VA, Khan D, Parthsarathy V, Flatt PR and Irwin N.An enzymatically stable GIP/xenin hybrid peptide restores GIP sensitivity, enhances beta cell function and improves glucose homeostasis in high-fat-fed mice. LID - 10.1007/s00125-016-4186-y [doi]. - Diabetologia.2016Dec21. Doi: 10.1007/s00125-016-4186-y., (1432-0428). 
  • Parthsarathy V, Irwin N, Hasib A, Martin C, McClean S, Bhat, B, Ng, M, Flatt, P, Gault V (2016) A novel chemically modified analogue of xenin-25 exhibits improved glucose-lowering and insulin-releasing properties. Biochim Biophys Acta. Doi (BBA)-General Subjects 1860 (4), 757-764.  
  • Martin C, Parthsarathy V, Hasib A, Ng, M, McClean S, Flatt, P, Gault V, Irwin N, (2016) Biological activity and antidiabetic potential of C-terminal octapeptide fragments of the gut-derived hormone Xenin. PLOS ONE, 11 (3), e0152818. 
  • Gault VA, Martin C, Flatt PR, Parthsarathy V, Irwin N (2015) Xenin-25[Lys13PAL]: A novel long-acting acylated analogue of xenin-25 with promising antidiabetic potential. Acta Diabetologica, 52 (3), 461-471.  
  • Martin C, Parthsarathy V, Pathak V, Gault VA, Flatt PR, Irvin N Characterisation of the biological activity of xenin-25 degradation fragment peptides. (2014). Journal of Endocrinology, 221 (2), 193-200.  
  • Parthsarathy V,  Hölscher  C  (2013)  Chronic  Treatment with  the  GLP1  Analogue  Liraglutide increases Cell Proliferation and Differentiation into Neurons in an AD Mouse Model. PLoS ONE 8(3): e58784. 
  • Parthsarathy V, McClean PL, Hölscher C, Taylor M, Tinker C, et al. (2013) A Novel Retro-Inverso Peptide Inhibitor Reduces Amyloid Deposition, Oxidation, and Inflammation and Stimulates Neurogenesis in the APPswe/PS1ΔE9 Mouse Model of Alzheimer’s Disease. PLoS ONE 8(1): e54769. 
  • Parthsarathy V  & Holscher  C (2013) The type 2 diabetes drug liraglutide reduces chronic inflammation induced by irradiation in the mouse brain.  European  Journal of  Pharmacology, 700(1-3), 42-50.  
  • McClean P, Parthsarathy V, Faivre E & Hölscher C (2011): The diabetes drug Liraglutide prevents   degenerative   processes   in   a   mouse   model   of   Alzheimer’s   disease.   Journal  of Neuroscience.,31 (17), 6587-6594.


  • O'Harte FPM, Parthsarathy V, Hogg C, Flatt P. Novel apelin analogues with beneficial in vitro and in vivo insulinotropic and glucose lowering properties. (Journal of Molecular Endocrinology ID: JME-17-0140).
  • Harnedy PA, Parthsarathy V, Mclaughlin CM, O’Keeffe MB, Allsopp PJ, McSorley EM, O'Harte FPM and FitzGerald RJ. Blue whiting (Micromesistius poutassou) muscle protein hydrolysate with in vitro and in vivo antidiabetic properties. Journal of Functional Food.

Recent conferences

  • ParthsarathyVadivel;O'Harte, Finbarr;  Hogg, Chris; Flatt, PeterThe synthetic analogue apelin-13 amide, improves acute glucose tolerance via activation of the APJ 308 receptor in diet induced obese diabetic mice. [Oral presentation, Irish Endocrine Society, 40th Annual meeting, 2017, Belfast] 
  • Parthsarathy, V; Mclaughlin, CM; Mullan, C; Harnedy, PA; Allsopp, PJ; McSorley, EM; FitzGerald, RJ and O’Harte, FPM (2015) Boarfish (Capros aperprotein hydrolysates show potent insulinotropic and GLP-1 secretory activity in-vitro and acute glucose lowering effects in-vivo. Diabetes UK conference 2015, Glasgow, Scotland, UK  
  • Parthsarathy, V; Mclaughlin, CM; Mullan, C; Harnedy, PA; Allsopp, PJ; McSorley, EM; FitzGerald, RJ and O’Harte, FPM (2015) Boarfish protein hydrolysates stimulate both insulin and GLP-1 secretion from cultured cells in vitro. Nutramara Conference, DublinIreland 

  • Parthsarathy, V and Holscher, C. (2011) Novel GLP1 analogue, Liraglutide reduces inflammation in mouse model with tissue injury, 41st Annual conference, Society for Neuroscience, Washington DC, USA and Scientific conference, Alzheimer’s Research UK, Birmingham, UK. 

  • Parthsarathy, V and Holscher, C. (2010) Chronic administration of Liraglutide reduces plaque loadand  inflammation  in  the  brains  of  APP/PS1  mice 40th Annual  conference,  Society for Neuroscience, San Diego, USA and Alzheimer’s Research UK, Southampton, UK. 

  • Presented my PhD work on role of GLP-1 analogue, liraglutide, on cell proliferation and inflammation in mouse brain, in Alzheimer’s association meeting, University of Ulster, Coleraine.

  • Presented a talk titled ‘Successful completion of PhD’ at Alzheimer’s Research UK annual conference (PhD day), Belfast, 2013.  

Experience in industry

None at present

International experience

None at present

Find out how to update your staff profile

Edit your staff profile